Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2015 financial results on February 10, 2016. Ligand’s CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.

Fourth Quarter and Full Year 2015 Earnings Call

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, hepatitis, ventricular fibrillation, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, asthma, focal segmental glomerulosclerosis, menopausal symptoms and osteoporosis. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Follow Ligand on Twitter @Ligand_LGND.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160122005209/en/

Ligand Pharmaceuticals Incorporated
Todd Pettingill
[email protected]
(858) 550-7500
or
LHA
Bruce Voss
[email protected]
(310) 691-7100

Source: Ligand Pharmaceuticals Incorporated

You May Also Be Interested In

• Benchmark on Take-Two's (TTWO) GTV 6 Release: 'we anticipate that the game will not be released within the fiscal year and expect it to launch in fiscal 2026 instead'
• AMCON Distributing (DIT) to Acquire Richmond Master Distributors
• Warren Buffet's Berkshire stock target raised at UBS into earnings